识别胰腺立体定向放射治疗(SBRT)中在线自适应预测因素
本研究回顾性分析了2016至2022年接受MRI引导胰腺SBRT的63个疗程(共315次分次),评估治疗前临床变量和模拟扫描剂量学参数能否预测在线自适应。单因素分析中处方剂量、GTV体积、胃V20/V25、十二指肠V20和最大剂量、大肠V33/V35、GTV最小剂量、PTV最小剂量和梯度指数与自适应显著相关(均p<0.05);多因素分析仅处方剂量显著(校正OR 19.7,p=0.005),但多重检验校正后未保持显著(p=0.08)。结论认为无法可靠预先预测需要在线自适应,提示解剖结构逐日变化的重要性。
要点
- 63个胰腺SBRT疗程315次分次中,58%(183/315)分次进行了在线自适应,中位每疗程自适应3次。
- 多因素分析仅处方剂量(>40 Gy vs ≤40 Gy)与自适应显著相关(校正OR 19.7,p=0.005),但多重检验校正后未保持显著(p=0.08)。
- 治疗前临床特征和模拟扫描剂量学参数无法可靠预测哪些患者需要在线自适应。
核心结论
- 无法可靠地使用治疗前临床特征、危及器官剂量学或基于模拟时解剖的其他剂量学参数预先预测需要在线自适应的可能性,提示解剖逐日变化的关键重要性以及增加胰腺SBRT自适应技术可及性的必要性。
- 较高的(消融)处方剂量与自适应使用增加相关。
研究设计与样本
- 回顾性研究,纳入2016至2022年接受MRI引导SBRT的患者,分析63个SBRT疗程共315次分次。
- 记录每个SBRT疗程的治疗前临床变量和模拟扫描剂量学参数,使用有序逻辑回归分析其预测在线自适应的能力,结局指标为自适应分次数。
主要发现
- 中位处方剂量为40 Gy分5次(范围33-50 Gy);52%的疗程处方≤40 Gy,48%的疗程处方>40 Gy。
- GTV和PTV的95%体积最小剂量(D95)中位数分别为40.1 Gy和37.0 Gy。
- 中位每疗程自适应分次数为3次,总计58%(183/315)的分次进行了自适应。
- 单因素分析中,处方剂量(>40 Gy vs ≤40 Gy)、GTV体积、胃V20和V25、十二指肠V20和最大剂量、大肠V33和V35、GTV最小剂量、PTV最小剂量和梯度指数均为自适应的显著决定因素(均p<0.05)。
- 多因素分析中,仅处方剂量显著(校正OR 19.7,p=0.005),但多重检验校正后未保持显著(p=0.08)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify any clinical or dosimetric parameters that predict which individuals may benefit from on-table adaptation during pancreas stereotactic body radiotherapy (SBRT) with MRI-guided radiotherapy. METHODS AND MATERIALS: This was a retrospective study of patients undergoing MRI-guided SBRT from 2016 to 2022. Pre-treatment clinical variables and dosimetric parameters on the patient's simulation scan were recorded for each SBRT course, and their ability to predict for on-table adaptation was analyzed using ordinal logistic regression. The outcome measure was number of fractions adapted. RESULTS: Sixty-three SBRT courses consisting of 315 fractions were analyzed. Median prescription dose was 40 Gy in five fractions (range, 33-50 Gy); 52% and 48% of courses were prescribed ≤40 Gy and >40 Gy, respectively. The median minimum dose delivered to 95% (D95) of the gross tumor volume (GTV) and planning target volume (PTV) was 40.1 Gy and 37.0 Gy, respectively. Median number of fractions adapted per course was three, with 58% (183 out of 315) total fractions adapted. On univariable analysis, the prescription dose (>40 Gy vs ≤40 Gy), GTV volume, stomach V20 and V25, duodenum V20 and dose maximum, large bowel V33 and V35, GTV dose minimum, PTV dose minimum, and gradient index were significant determinants for adaptation (all p < 0.05). On multivariable analysis, only the prescription dose was significant (adjusted odds ratio 19.7, p = 0.005), but did not remain significant after multiple test correction (p = 0.08). CONCLUSIONS: The likelihood of needing on-table adaptation could not be reliably predicted a priori using pre-treatment clinical characteristics, dosimetry to nearby organs at risk, or other dosimetric parameters based on the patient's anatomy at the time of simulation, suggesting the critical importance of day-to-day variations in anatomy and increasing access to adaptive technology for pancreas SBRT. A higher (ablative) prescription dose was associated with increased use of adaptation.
引用
- Wu TC, Yoon SM, Cao M, et al. Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT). Clin Transl Radiat Oncol. 2023. PMID: 36896266. doi:10.1016/j.ctro.2023.100603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。